Oscar Health, Inc. (OSCR) Down 5.2% — Is It Smart to Take Money Off the Table?
Oscar Health, Inc. (OSCR) slid lower on Friday, closing at $31.74 on the NYSE, a $1.73 decline from the prior close of $33.47. The selloff came just days after the stock set a fresh 52-week high of $35.01 on October 13, 2026. Friday's close leaves OSCR roughly 9.3% below that peak, which means the stock has given back a meaningful share of its recent gains in only three sessions.
Volume came in at roughly 3.82 million shares, well below the 90-day average of about 5.54 million. The decline unfolded on about 69% of normal turnover, so the selling was steady but not a broad rush for the exits.
Why Oscar Health, Inc. Price is Moving Lower
The most plausible driver is renewed concern that rising Affordable Care Act premiums will strain affordability and enrollment in Oscar's core market. Finalized Georgia marketplace rates reported on October 16 put Oscar's average 2027 premium increase at nearly 29%, the largest among the state's eight marketplace insurers, with an average monthly premium near $960. A hike of that size raises a direct question for a company built around the individual market: how many members will stay enrolled when their bills climb that sharply?
The broader enrollment data makes that question harder to dismiss. KFF reported on October 14 that individual-market enrollment fell 18%, from 25.2 million in June 2025 to 20.5 million in June 2026. Over the same stretch, insurers proposed a 15% median premium increase for 2027. Oscar's Georgia filing sits well above that median, which sharpens concern that its pricing could push members away just as the overall pool is shrinking. The pressure looked specific to Oscar rather than sector-wide. The Health Care Select Sector SPDR (XLV) slipped only about 0.45% in afternoon trading, while Financials peers The Progressive Corporation (PGR) gained 2.22% and The Travelers Companies, Inc. (TRV) added 1.47%.
The decline comes despite strong recent results. Oscar's Q2 report on August 6 showed EPS of $1.10 against a $0.40 estimate. Revenue reached $4.88 billion versus the $4.73 billion consensus, up 70.4% year over year. Net income swung to $361.8 million from a $228.4 million loss a year earlier. At its September 16 Investor Day, management raised its 2026 operating-earnings outlook to $600 million to $800 million, up from $500 million to $700 million, while holding revenue guidance at $18.7 billion to $19.0 billion. The open question is whether that profitability can hold up in 2027 if steeper premiums erode the membership base. With the stock trading at a forward P/E of 24.14, investors appear less willing to pay up for that uncertainty ahead of Q3 results on November 5.
What is the Oscar Health, Inc. Rating - Should I Sell?
Weiss Ratings assigns OSCR a B- rating. Current recommendation is Buy. That rating reflects a company whose fundamentals have improved sharply over the past year, tempered by the price instability that comes with heavy exposure to a single, policy-sensitive market. Friday's decline does not change the underlying profile, but it shows the kind of risk that keeps the rating at B- rather than higher.
The strongest support comes from the balance sheet and from shareholder returns. Oscar is rated Excellent on the Solvency Index, which matters for an insurer that must hold sufficient reserves against medical claims while expanding rapidly. The swing from a $228.4 million loss to $361.8 million in quarterly net income strengthens that capital position. The Excellent rating on the Total Return Index reflects a stock that set a 52-week high of $35.01 just this week, a level that would have been hard to imagine while the company was still posting losses. The Good ratings on the Growth and Efficiency indices round out a solid fundamental picture. Revenue growth of 70.4% and a 34.26% ROE are standout figures for a health insurer that only recently reached consistent profitability. The thin 3.59% profit margin explains why neither index is rated higher, since most of every premium dollar flows out as medical costs. Growth is also likely to be tested if 2027 enrollment contracts.
The weak spot is the Volatility Index, rated Weak. A 5.17% drop on a single state's rate filing and an enrollment report, while the health care sector barely moved, shows how sensitive OSCR is to ACA policy and pricing headlines. That sensitivity is the main reason the overall rating sits at B- despite Excellent marks for solvency and returns.
Within the Financials sector, Oscar Health is on par with The Progressive Corporation (PGR, B-) and Ping An Insurance (Group) Company of China, Ltd. (PNGAY, B-). It trails MetLife, Inc. (MET, B), The Travelers Companies, Inc. (TRV, A+), and Manulife Financial Corporation (MFC, A+), all of which combine strong fundamentals with steadier trading histories.
About Oscar Health, Inc.
Oscar Health, Inc. (OSCR) is a Financials company operating within the Insurance industry and built around a technology-first approach to health coverage. Founded in 2012 and headquartered in New York City, Oscar focuses primarily on the individual and family marketplace created under the Affordable Care Act. It sells health plans directly to consumers across numerous states and also serves employers through small-group coverage and Individual Coverage Health Reimbursement Arrangement (ICHRA) offerings, which let businesses fund individual-market plans for their workers.
Oscar's distinguishing feature is its proprietary technology stack, which it uses to manage member engagement, claims, and care navigation. Members get access to virtual care, dedicated Care Teams that help them find providers and manage costs, and a mobile app designed to simplify a process most consumers find opaque. The company also licenses its platform to other healthcare organizations through +Oscar, turning internal infrastructure into an additional line of business.
Oscar's competitive advantage rests on its scale in the ACA marketplace and on member-experience technology that legacy insurers have been slower to match. That focus cuts both ways. Concentration in the individual market gives Oscar deep expertise and strong growth when enrollment expands, but it also leaves the company more exposed than diversified insurers to subsidy policy, premium affordability, and shifts in marketplace participation.
Investor Outlook
Oscar Health, Inc. (OSCR) carries a Weiss Rating of B- (Buy), supported by strong solvency, exceptional recent returns, and a sharp turn to profitability, though Friday's decline shows how quickly ACA affordability concerns can weigh on the shares. Investors should watch the November 5 Q3 report for any commentary on 2027 enrollment expectations and on how the nearly 29% Georgia premium increase compares with Oscar's pricing in other states. See full rankings of all B- rated Financials stocks inside the Weiss Stock Screener.
--